RT Journal Article
SR Electronic
T1 Critical Challenges in Pluvicto Therapy: Incontinent and Anticoagulated Patients
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP 279
OP 281
DO 10.2967/jnmt.123.266482
VO 51
IS 4
A1 Crowley, James R.
YR 2023
UL http://tech.snmjournals.org/content/51/4/279.abstract
AB As molecular therapy continues to grow, unanticipated challenges may arise, requiring the institution’s therapeutic team to reevaluate its therapeutic protocol to identify and address potential situations and challenges that may occur. This practical pointer will focus on the novel prostate cancer therapy Pluvicto (177Lu-vipivotide tetraxetan) and 2 unique situations and challenges of treating patients at the Theranostic Center at Carilion Clinic, an outpatient facility dedicated to targeted molecular therapy.